Form 8K Baxter International Inc. For: 19 November By Investing.com
This article announces that Baxter International Inc. filed a Form 8K on November 19, 2026. The filing is a standard regulatory disclosure, often used to announce significant events that investors should know about. No specific details about the content of the 8K are provided within the article.
Form 8K Baxter International Inc. For: 19 November By Investing.com
This article reports on Baxter International Inc.'s Form 8K filing for November 19, 2026. The brief announcement provides no specific details about the content of the filing but indicates its public availability. The article is from Investing.com and was published on November 19, 2026, at 07:22 pm.
Baxter Highlights Turnaround Progress, Raises 2026 Organic Sales Guidance to 3%–4%
Baxter reported significant progress in its turnaround efforts, leading to a raised organic sales growth guidance for 2026 to 3%–4%. The company also achieved $705 million in year-to-date free cash flow and completed a $600 million cash tender offer, retiring $864 million of debt, putting it on track for its 3.0x net leverage target by year-end. Additionally, Baxter announced new sustainability targets, aiming for net-zero Scope 1 and 2 emissions by 2050 and 100% renewable electricity by 2040.
HCA Healthcare and Learning Undefeated Bring Mobile STEM Lab to Herndon High School
HCA Healthcare and Learning Undefeated partnered to bring a 1,000-square-foot Mobile Exploration Lab to Herndon High School, offering students hands-on experience in healthcare careers. Students engaged in an interactive activity mirroring real-world patient care, focusing on diabetes and glucose monitoring. The initiative aims to inspire the next generation of healthcare talent in Northern Virginia and showcase diverse career opportunities beyond traditional doctor and nurse roles.
CTSO - Cytosorbents Corp Latest SEC Filings
This article provides a detailed overview of Cytosorbents Corp (CTSO), including its latest SEC filings, stock performance, and key financial metrics. It covers various data points such as market capitalization, enterprise value, income, sales, earnings per share, and insider/institutional ownership. The information aims to give investors a comprehensive snapshot of the company's current financial health and market position.
How Baxter Boosts Medical Circularity And Net Zero Targets
Baxter, a leading medical technology company, is striving for both medical circularity and net zero emissions by 2050, despite the challenges of maintaining strict sterility standards for its products. Chief Sustainability Officer Renae Kerzar explains how Baxter integrates material reduction into product engineering, collaborates with healthcare systems to manage waste, and implements a global plan to decarbonize its operations, aiming for 100% clean, renewable electricity by 2040. The company also emphasizes the importance of "double materiality" to align sustainability efforts with financial and risk management goals, and partners with other healthcare organizations to advance circularity and reduce emissions across the supply chain.
Development company elects new chairperson
John Cannon has been elected as the new chairperson of South West Mayo Development Company (SWMDC), bringing experience in corporate management and community work. Donna Hyland was elected vice-chairperson. SWMDC manages the LEADER rural development programme, oversees employment schemes, and administers social inclusion funds, with CEO Sabina Trench highlighting the board's diverse expertise.
Biofrontera posts 30% revenue growth in Q3 2026, driven by FDA approval and product sales expansion.
Biofrontera Inc. reported a significant 29.8% increase in net product revenue for Q3 2026, reaching $9.1 million. This growth was primarily fueled by the FDA's approval of Ameluz for superficial basal cell carcinoma and a favorable ruling regarding its RhodoLED XL-C lamp. The company plans further commercialization of Ameluz for new indications in late 2026 and early 2027 to expand its presence in the dermatology market.
Edwards Lifesciences Corporation (EW) stock price, news, quote and history
Edwards Lifesciences Corporation (EW) stock is currently trading at $107.15, up 1.28%, with an after-hours price of $106.50. The company, a medical device provider specializing in cardiovascular diseases, has seen a YTD return of 25.69% and a 1-year return of 24.43%. Analysts have an average price target of $113.39, with TD Cowen recently raising its price target to $121 and maintaining a Buy rating.
Argus Research Maintains Baxter International Inc(BAX.US) With Hold Rating
Argus Research has maintained its "Hold" rating on Baxter International Inc. (BAX.US). This indicates that the research firm advises investors to neither buy nor sell the stock at the current time, suggesting a neutral outlook on the company's performance.
Former Medtronic and Baxter International Executives Join Chapman & Co. Leadership Institute, Expanding Healthcare and MedTech Expertise
Chapman & Co. Leadership Institute has announced the addition of Jeanne Mason, former executive vice president and chief human resources officer of Baxter International, and Carla Skinner, former senior director of Medtronic's Global Sales Excellence, to its senior leadership team. This expansion aims to bolster the firm's expertise in healthcare, life sciences, and MedTech organizations, bringing decades of experience in leadership development, culture transformation, and organizational change. Their appointments are set to enhance the consultancy's ability to help clients align strong culture with robust business results in complex and highly regulated industries.
City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease
City Therapeutics has dosed the first participant in its phase 1 trial of CITY-RBP4, an investigational RNA interference (RNAi) therapeutic for Stargardt disease type 1 (STGD1). This therapy aims to silence RBP4 expression in the liver to reduce vitamin A delivery to the eye and slow retinal damage. The milestone occurs as the FDA reviews Belite Bio’s tinlarebant, another RBP4-targeting therapy, for potential approval, highlighting a rapidly advancing pipeline for Stargardt disease.
Chapman & Co. Adds Former Medtronic, Baxter Executives
Chapman & Co. Leadership Institute has announced the addition of Jeanne Mason, former EVP and Chief HR Officer of Baxter International, and Carla Skinner, former Senior Director of Medtronic's Global Sales Excellence, to its senior leadership team. Their expertise in leading high-performing teams and culture transformation in global medical technology companies will enhance the firm's ability to serve healthcare, life sciences, and MedTech organizations. This move aims to help clients navigate industry pressures, accelerate transformation, and improve organizational performance by aligning strong culture with strong business results.
Washington Sues Major Dialysis Providers Over Noncompete Agreements
Washington State has filed a lawsuit against DaVita Inc. and Fresenius Medical Care Holdings Inc., two major dialysis providers, over alleged unlawful noncompete agreements. Attorney General Nick Brown claims these agreements, which restrict nephrologists serving as part-time medical directors from working at competing centers, limit competition and patient access to care for the approximately 9,000 Washington residents receiving dialysis. The state seeks to invalidate the agreements and impose financial penalties, with DaVita disputing the allegations.
Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced the sale of its 1,000th superficial radiotherapy (SRT) system, a major commercial milestone. This achievement underscores the company's commitment to providing non-invasive treatment options for non-melanoma skin cancer and reflects increased physician awareness and dedicated reimbursement codes for SRT. Sensus Healthcare plans to continue expanding access to this technology, aiming for the next 1,000 units.
Nortech Systems Secures Patents for Optical Interconnects Built for MRI and Aerospace Environments
Nortech Systems Incorporated has been granted two U.S. patents for its active optical cable technology, designed for high-speed fiber optic connectivity in challenging environments like strong magnetic fields and sensitive electrical systems. The patents cover a non-magnetic optical connector and built-in cable diagnostics that can be paused during noise-sensitive operations. This innovation addresses critical engineering challenges for medical imaging, aerospace, and defense customers, enabling reliable product development.
CoreCivic EVP Anthony L. Grande Sells 25,000 Shares at $31.49 on November 10, 2026
CoreCivic's Executive Vice President and Chief Development Officer, Anthony L. Grande, sold 25,000 shares of company common stock on November 10, 2026, at a weighted average price of $31.49 per share. This transaction, detailed in a Form 4 filing, leaves Grande with 119,782 directly held shares. The individual sale prices for the shares ranged from $31.26 to $31.61.
Orthofix Q3 Revenue Misses Estimates by $2.62 Million as EPS Beats
Orthofix Medical Inc. reported third-quarter revenue of $207.9 million, missing analyst estimates by $2.62 million, despite a 1.1% year-over-year increase. The company's GAAP loss per share of $0.15 was 12 cents better than expected. Cash and cash equivalents decreased sequentially to $86.9 million from $104.4 million due to working-capital timing.
PR News | JF, FTI Work $6B Healthcare Deal - Mon., Nov. 9, 2026
Joele Frank is representing HealthSpan Partners in its updated $25 per share bid for Surgery Partners, a deal valued at $6 billion. FTI Consulting is advising Surgery Partners, which rejected a higher $28-per-share offer from a third party due to longer completion times and increased regulatory risk. Bain Capital, holding a 38 percent stake in Surgery Partners, supports the HealthSpan merger.
Topical Hemostatic Agents Market Size, Share & Forecast 2036
The topical hemostatic agents market is projected to grow from USD 3.37 billion in 2026 to USD 6.3 billion by 2036, at a CAGR of 6.5%. This growth is driven by increasing surgical procedures and the need for specialized bleeding control materials. Gelatin-based products, surgical wound care applications, and hospitals are expected to remain the dominant segments, with the UK, Japan, and Brazil showing the highest growth rates.
Alcon stock faces earnings test after Pershing Square backs margins
Alcon stock is entering its next quarterly report with investor attention focused on margins and guidance, particularly after Pershing Square expressed a bullish view on the company's margin expansion and raised full-year outlook. The upcoming earnings release will assess the durability of sales momentum, profitability, and demand in Alcon's Surgical and Vision Care businesses. Investors are keen to see if the recent margin gains translate into sustained earnings growth.
Baxter International Inc. stock outperforms competitors on strong trading day
Shares of Baxter International Inc. (BAX) rose 2.40% to $26.41, outperforming competitors and the broader market on a strong trading day. This marks the second consecutive day of gains for the stock, as the S&P 500 Index and Dow Jones Industrial Average also saw significant increases.
Barclays maintains Baxter International at Underweight, raises price target to $23 from $20
Barclays has reiterated its "Underweight" rating for Baxter International (BAX) while increasing its price target from $20 to $23, a 15% rise. Despite the increase, the new price target suggests a 10.8% downside from the stock's closing price of $25.79 on November 6. Investors can find more detailed analyst ratings and price target data for Baxter International on TradingView's Forecasts tab.
Baxter International (BAX) Could Be 5% Undervalued After Profit Return And Higher Outlook
Baxter International (BAX) has recently reported a shift from a loss to a profit in its third-quarter results and has increased its 2026 sales growth outlook. This positive news, coupled with recent share price gains, suggests improving business health, leading analysts to consider the stock modestly undervalued by about 5%. However, potential risks like Novum IQ pump field actions or FDA manufacturing concerns could affect this positive outlook.
Axogen (AXGN) Raised Its 2026 Outlook, Is The Upside Already Priced In?
Axogen (AXGN) has seen a significant stock rally following strong third-quarter results, raised 2026 revenue guidance, and an update on its prostate program. Despite a 30-day return of 38.44% and a year-to-date gain of 61.35%, Simply Wall St's analyst consensus suggests the stock is still 13% undervalued based on a fair value of $57.73. However, a high P/S ratio of 11.2x compared to sector averages raises questions about whether the good news is already reflected in the price, especially given its reliance on a biologic-driven nerve repair portfolio.
Weekly Recap: Albumin revenue falls and Canadian collections restart
Grifols (GRF) reported a decline in albumin revenue for the third quarter and first nine months of 2026, citing a slow recovery in China. Concurrently, the company has begun a phased restart of plasma collection at its 17 Canadian centers after a temporary pause. Grifols also achieved €208 million in third-quarter free cash flow before M&A and does not anticipate an update on its potential U.S. Biopharma IPO review until 2027.
What STERIS (STE) Said on Its Q2 Earnings Call
STERIS (STE) raised its fiscal 2027 earnings outlook after reporting strong second-quarter revenue and profit, driven by tariff refunds and robust Life Sciences equipment shipments. The company now expects diluted EPS of $11.35 to $11.55 and maintained its full-year revenue growth forecast. STERIS also announced a planned acquisition of Xodus Medical to expand its consumables offering and a restructuring plan to achieve annualized savings.
How Return To Profitability At Baxter International (BAX) Has Changed Its Investment Story
Baxter International reported a return to profitability in Q3 2026 with US$294 million net income and raised full-year sales growth guidance to 4-5%, indicating successful cost actions and portfolio adjustments. The company's investment narrative now focuses on whether operational improvements are durable, with attention on sustained hospital consumable demand and core therapies, amidst risks like ongoing infusion system disruptions and tariff headwinds. Analysts project future revenue of US$12.6 billion and earnings of US$829.1 million by 2029, suggesting a significant turnaround from previous losses.
Marjorie Smith Obituary (1930 - 2026) - Manchester, CT - Journal Inquirer
Marjorie K. Smith, 96, of Manchester, CT, passed away on November 4, 2026. Known for her strong family values, exceptional organizational skills, and dedication to her community, she leaves behind a legacy of love and hard work. Visitation and a funeral home service are scheduled for Wednesday, November 11, 2026, at John F. Tierney Funeral Home in Manchester.
Fresenius Medical Care stock gains 4.5% as outlook narrows
Fresenius Medical Care stock gained 4.5% over the week after the company narrowed its 2026 operating-income outlook due to declining US treatment volumes. Despite efficiency measures and progress in kidney-care technology, third-quarter operating income declined, also impacted by one-off China strategy costs. Investors are now focused on the stabilization of US treatment volumes and the effectiveness of transformation savings.
Baxter International Inc. stock underperforms Thursday when compared to competitors
Shares of Baxter International Inc. (BAX) fell by 3.21% on Thursday, closing at $25.65. This underperformance occurred during a generally negative trading session where the S&P 500 Index (SPX) dropped 4.36% and the Dow Jones Industrial Average (DJIA) declined 3.44%. The stock's downturn ended a three-day winning streak.
Smith & Nephew guidance cut and weak wound care sales point to share fall, says Jefferies
Jefferies, the investment bank, expects shares in Smith & Nephew PLC to experience a short-term fall following weaker-than-expected third-quarter sales and a cut to the company's full-year guidance. The medical devices group reduced its organic sales growth guidance to about 3% from 4% and trading profit guidance to about $1.25 billion from $1.3 billion. Despite the expected short-term dip, Jefferies maintains a 'buy' rating and a 1,500p price target for the stock.
Smart Hospital Beds Market Size, Share & Forecast 2036
The smart hospital beds market is projected to grow from USD 1.34 billion in 2026 to USD 2.92 billion by 2036, exhibiting a CAGR of 8.1%. This growth is driven by increasing focus on patient safety, demand for advanced ICU beds, and hospital digitalization. Fully automatic beds and wireless technology are expected to dominate the market segments, with hospitals being the leading end-user.
Baxter International stock trades at 23.62 euros late Wednesday
Baxter International stock traded at 23.62 euros on Lang & Schwarz late Wednesday, a slight increase from its previous close. The healthcare company specializes in connected solutions, medical devices, and injectable medicines, serving various care settings globally. The article highlights Baxter's focus on connected care and its wide range of products used in hospitals, dialysis centers, and home-based care.
BW Altor Fully Exits Cadeler A/S Stake Following UK Redomiciliation Completion
BW Altor Pte. Ltd. has fully divested its stake in Cadeler A/S following the completion of Cadeler's redomiciliation from Denmark to the United Kingdom. BW Altor exchanged all 109,352,091 Cadeler A/S shares for an equal number of newly issued Cadeler plc shares and also made open market purchases of Cadeler plc shares. As of November 2, 2026, BW Altor no longer holds any ordinary shares in Cadeler A/S.
Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona shares are soaring, what you need to know
Shares of Stryker, Omnicell, Zimmer Biomet, Artivion, and Dentsply Sirona surged following election results that confirmed Democratic majorities in the House and Senate, alleviating regulatory concerns about drug pricing. Wall Street analysts expect a strengthened biopharmaceutical sector recovery, as new drug pricing legislation is deemed unlikely. Zimmer Biomet, in particular, saw a 15.2% jump and recently hit a new 52-week high after increasing its share repurchase expectations.
What Sotera Health (SHC) Said on Its Q3 Earnings Call
Sotera Health (SHC) reported solid third-quarter 2026 results, with revenue up 4.4% to $325 million and adjusted EBITDA increasing 3.9% to $171 million, driven by strong performance in Sterigenics and Nelson Labs. Despite reaffirming its full-year outlook, the company noted softer demand from medical-device customers in Europe late in Q3 and continuing into Q4. Nordion revenue declined due to Cobalt-60 harvest timing, but still exceeded expectations.
Should You Buy Baxter Stock For Its Cash?
Baxter International (BAX) currently offers a high free cash flow yield of 9.1%, significantly above the S&P 500 median, suggesting it could be undervalued or facing future challenges. While management has raised its 2026 sales outlook, the company's operating margin has thinned, and its significant debt is being actively paid down. Investors should monitor Baxter's free cash flow and net leverage in its upcoming report to assess if its strong cash generation is sustainable beyond one-time benefits like tariff refunds and legal settlements.
Smith+Nephew Drops Its Outlook As J&J Talks End
Smith+Nephew cut its full-year sales and profit outlook due to a slowdown in its orthopaedics unit, which accounts for 40% of its sales. The company confirmed that merger discussions with Johnson & Johnson's orthopaedics business have ended, reportedly due to disagreements over leadership. This development complicates the valuation of Smith+Nephew's orthopaedics division, potentially leading to a "strategic review" discount on its stock.
Baxter International Inc. (BTL.F) Seasonal returns chart
This Yahoo Finance article presents a seasonal returns chart for Baxter International Inc. (BTL.F), showcasing the average monthly price return for the period between 2016 and 2026. The stock is currently trading at 22.22 EUR, up 7.55%. The article also provides various related market data and company information links.
X4 Pharmaceuticals to present at three major healthcare conferences in November 2026
X4 Pharmaceuticals announced its participation in three major healthcare investment conferences in November 2026: Guggenheim, Stifel, and Jefferies. The company will provide updates on its therapies for rare hematology diseases, including its approved drug XOLREMDI® for WHIM syndrome and ongoing Phase 3 trials for chronic neutropenia. These presentations offer an opportunity for X4 to engage with investors and showcase its advancements and market potential.
Rockwell Medical agrees to buy most of Vantive's hemodialysis business for $125 million
Rockwell Medical has agreed to acquire the majority of Vantive's hemodialysis business for $125 million in base consideration, with an additional $45 million in contingent payments. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility, with the combined entity projected to generate $400-450 million annually. Vantive will retain its dialyzer portfolio and focus on home dialysis and critical care post-divestiture, while Rockwell aims to accelerate its growth in hemodialysis.
Rockwell Medical to Acquire Vantive Hemodialysis Business for Up to $170 Million
Rockwell Medical (Nasdaq: RMTI) has agreed to acquire Vantive’s global hemodialysis products and operations for up to $170 million, including contingent payments, aiming to transform itself into a diversified global provider. The acquisition, which includes a $125 million base price, is expected to significantly expand Rockwell's manufacturing capabilities, international presence, and product portfolio. This strategic move is projected to close in mid-2027, making Rockwell Medical a comprehensive supplier of hemodialysis equipment, consumables, and services.
Baxter International Inc. (BAX) Seasonal returns chart
This article provides a seasonal returns chart for Baxter International Inc. (BAX), showcasing the average monthly price return from 2016 to 2026. It also includes current stock performance data, with the stock trading at $24.22, up 5.30% at close, and $24.32, up 0.41% overnight. The information is sourced from Yahoo Finance, detailing real-time price and historical seasonality.
Diwali Stock Picks 2026: BEL, SBI, Blue Star, Infosys Among Monarch Networth's Top 14 Bets For Samvat 2083
Monarch Networth Capital has released 14 stock recommendations for Diwali Muhurat trading on November 8, spanning sectors such as banking, defence, healthcare, technology, capital goods, and consumer durables. Key picks include Bharat Electronics (BEL), State Bank of India (SBI), Blue Star, and Infosys. Carborundum Universal and CCL Products show the highest upside potential at 52% each.
Baxter International Inc. (BTL.F) Seasonal returns chart
This article provides a seasonality chart for Baxter International Inc. (BTL.F), displaying the average monthly price return between 2016 and 2026. The data presented is a delayed quote from the Frankfurt market, showing the stock price at 19.96 EUR as of November 2, 2026, at 3:25:02 pm GMT+1.
Baxter International Inc. stock outperforms competitors on strong trading day
Baxter International Inc. (BAX) shares rose 5.30% to $24.22 on Monday, outperforming the mixed stock market where the Dow Jones Industrial Average gained 0.41% but the S&P 500 Index fell 0.51%. This gain ended a two-day losing streak for the company's stock.
Catheter Precision Announces New FDA 510(k) Clearance for its VIVO System, Enabling Use in a Broader Patient Population
Catheter Precision, a subsidiary of Flyte Aviation, Inc., announced that its VIVO system received FDA 510(k) clearance for expanded use in patients with structural heart disease undergoing catheter ablation for monomorphic ventricular tachycardia. This clearance allows the VIVO system to be used in a broader patient population, improving pre-procedural planning and potentially reducing procedure times and optimizing patient outcomes. The VIVO system is a non-invasive 3D imaging system designed to identify the origin of ventricular arrhythmias prior to an electrophysiology procedure.
Ingersoll Rand Expands Life Sciences Solutions with Acquisition of IVEK Corporation
Ingersoll Rand Inc. (NYSE: IR) has acquired IVEK Corporation, a U.S.-based designer and manufacturer of small-volume precision liquid metering and dispensing systems. This acquisition enhances Ingersoll Rand's life sciences portfolio, particularly in precision fluid control for healthcare, diagnostics, medical device, and biomedical industries. The deal is expected to add approximately $40 million in annual revenue and was made at an attractive low-double digit pre-synergy purchase multiple of 2025 Adjusted EBITDA.
AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry
Heartflow announced prospective clinical outcomes from its DECIDE registry, demonstrating that its AI-powered plaque analysis reduced major cardiovascular disease events by 34% and myocardial infarction rates by half at one year, compared to CCTA alone. The platform facilitated earlier optimization of drug regimens, leading to a 41% early increase in patients achieving LDL-C goals. Additionally, the GAMEFILM registry revealed a high prevalence of hidden heart disease in retired NFL players, with 85% having detectable plaque, often soft and missed by traditional scans, highlighting the need for advanced assessment.